Renal cell carcinoma (Q73669457)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

review article

1 reference

title

Renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

R J Motzer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

P Russo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

D M Nanus

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

W J Berg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 July 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

Current Problems in Cancer

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

185-232

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Estimates of the worldwide incidence of eighteen major cancers in 1985.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

International renal-cell cancer study. II. Analgesics.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

International renal-cell cancer study. V. Reproductive factors, gynecologic operations and exogenous hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

International renal-cell cancer study. IV. Occupation.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

International renal cell cancer study. VII. Role of diet

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

International renal-cell cancer study. I. Tobacco use

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Nutrition and renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

High incidence of papillary renal cell tumours in patients on chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Malignant renal tumors in tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Risk factors for renal cell carcinoma in Denmark. I. Role of socioeconomic status, tobacco use, beverages, and family history

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

von Hippel-Lindau disease affecting 43 members of a single kindred

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Hereditary Renal-Cell Carcinoma Associated with a Chromosomal Translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Hereditary papillary renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3;8 translocation. Genetics of familial renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Diagnosis and management of renal cell carcinomaA clinical and pathologic study of 309 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Clinical significance of erythropoietin levels in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Common expression of parathyroid hormone-related protein and no correlation of calcium level in renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Non-metastatic hepatic dysfunction associated with renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Incidentally detected renal cell carcinoma: role of ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Unrecognized renal cell carcinoma. Clinical and diagnostic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal cell carcinoma as an incidental finding

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal cell carcinoma: earlier discovery and increased detection

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Clinical analysis of incidentally found renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

A Survey on Incidental Renal Cell Carcinoma in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Effect of improved diagnosis of renal cell carcinoma on the course of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Cytogenetic analysis of epithelial renal-cell tumors: relationship with a new histopathological classification

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Adult renal epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Chromophobe cell carcinoma of the kidney. A clinicopathologic study of 21 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Morphological classification of renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Prognostic significance of morphologic parameters in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Cytogenetics of papillary renal cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Low chromosome number in chromophobe renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Chromophobe Cell Renal Carcinoma: Clinicopathological Features of 50 Cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Collecting duct carcinoma of the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Small renal cell carcinomas: resolving a diagnostic dilemma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

The small (less than or equal to 3.0 cm) renal parenchymal tumor: detection, diagnosis, and controversies

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

The current radiological approach to renal cysts.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal adenocarcinoma: CT staging of 100 tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

The results of radical nephrectomy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal Carcinoma: Computer Analysis of 96 Patients Treated by Nephrectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Stratification of risk factors in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Long-term results of resection of renal cell cancer with extension into inferior vena cava

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Surgical management and prognosis of renal cell carcinoma invading the vena cava

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Radical nephrectomy in patients with renal cell carcinoma with venous, vena caval, and atrial extension

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Role of lymphadenectomy in the treatment of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Factors influencing adrenal metastasis in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Is ipsilateral adrenalectomy a necessary component of radical nephrectomy?

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Adrenal involvement from renal cell carcinoma: predictive value of computerized tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Kidney preserving surgery in renal cell tumors: indications, techniques and results in 152 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Conservative surgery of renal cell tumors in 140 patients: 21 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Nephron sparing surgery in incidental versus suspected renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Expanding indications for conservative renal surgery in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Conservation surgery of renal carcinoma: the EIRSS experience

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Current controversies in nephron-sparing surgery for renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Partial nephrectomy for renal cell carcinoma: indications, results and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Partial nephrectomy for renal cell carcinoma with a normal opposite kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Distant metastasis of renal adenocarcinoma in nephrectomized cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Prognostic implications of vena caval extension of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal cell carcinoma.Natural history and results of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Local Recurrence After Nephrectomy for Primary Renal Cancer: Computerized Tomography Recognition

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Results of surgical treatment of renal cell carcinoma with solitary metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal cell carcinoma: survival and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Aggressive versus conservative management of stage IV renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Prognostic factors in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Surgery for Metastatic Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal cell carcinoma--a review of 256 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Renal cell carcinoma: late recurrence in 2 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Validity of kidney-preserving surgery for localized renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Intraoperative sonography: application in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Intraoperative renal ultrasonography: a useful adjunct to partial nephrectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Current status of the therapy of advanced renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Circadian Infusion of Floxuridine in Patients with Metastatic Renal Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Proceedings: Hormone-induced and spontaneous regression of metastatic renal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Hormone receptors in renal cell carcinoma. Their utility as predictors of response to endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Infarction-nephrectomy for metastatic renal carcinoma. Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma).

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Hormones in the Treatment of Metastatic Renal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Hormonal therapy of renal carcinoma alone and in association with cytostatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

CCNU, vinblastine, and delalutin therapy in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). Brazilian Oncology Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Modulation of multidrug resistance: at the threshold

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Interferon treatment of renal cell carcinoma. Current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Familial renal cell carcinoma: clinical and molecular genetic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Identification of the von Hippel-Lindau disease tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Tumour suppression by the human von Hippel-Lindau gene product

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Infrequent involvement of p53 mutations and loss of heterozygosity of 17p in the tumorigenesis of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Polymerase chain reaction-single strand conformation polymorphism analysis of the p53 gene in paraffin-embedded surgical material from human renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Infrequent ras oncogene point mutations in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Tumor suppressor gene allelic loss in human renal cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Analysis of nm23 gene expressions in human bladder and renal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Expression of nm23 in cell lines derived from patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Analysis of genetic alterations in renal cell carcinoma using the polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

International renal‐cell cancer study. VIII. Role of diuretics, other anti‐hypertensive medications and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Phase II Study of Five-Day Continuous Infusion of Vinblastine in Patients With Metastatic Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Hormonal therapy in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Hormonal Treatment of Metastases of Renal Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Proceedings: Chemotherapy of adenocarcinoma of the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Medical treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0147-0272%2897%2980007-4

7 January 2021

10.1016/S0147-0272(97)80007-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9285186%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference